Table 1.
General information of the patients at initial LM diagnosis.
| Characteristic | N (%) |
|---|---|
| Gender | |
| Male | 77 (47%) |
| Female | 86 (53%) |
| Median age | 57 yrs (range 21–76 yrs) |
| Pathological features of the primary disease | |
| Pulmonary adenocarcinoma | 84 (52%) |
| Pulmonary adenosquamous carcinoma | 3 (2%) |
| Squamous cell lung cancer | 7 (4%) |
| SCLC | 29 (18%) |
| Breast cancer | 26 (16%) |
| Gastric adenocarcinoma | 7 (4%) |
| Others* | 5 (3%) |
| Median KPS | 40 (range 10–100) |
| GCS | |
| 15 | 87 (53%) |
| 13~14 | 53 (33%) |
| 9~12 | 23 (14%) |
| Median time interval between diagnosis of primary tumors and LM | 13 months (range 0–109 months) |
| LM as initial manifestation of cancer | 19 (12%) |
| Pulmonary adenocarcinoma | 14 (74%) |
| Gastric adenocarcinoma | 2 (11%) |
| SCLC | 2 (11%) |
| Primary intracranial melanoma | 1 (5%) |
| Systemic disease status | |
| Stable | 59 (36%) |
| Free | 17 (10%) |
| Active | 77 (47%) |
| Unevaluated | 10 (6%) |
SCLC, small cell lung cancer; KPS, Karnofsky performance score; GCS, Glasgow Coma Scale.
*Including double primary cancers of breast cancer and lung cancer (n = 1), hepatocellular carcinoma (n = 1), laryngeal squamous cell carcinoma (n = 1), rhabdomyosarcoma of paranasal sinus and nasal cavity (n = 1), primary intracranial melanoma (n = 1).